Navigation Links
Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
Date:3/6/2012

id loss of cellular energy and leads to the inhibition of both mammalian target of rapamycin (mTOR1 and mTOR2) pathways. In April 2011, Ayesha Alvero, M.D., Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine, presented data at the American Association for Cancer Research Annual Meeting from a pre-clinical study of NV-128 demonstrating its ability to induce mitochondrial instability, ultimately leading to cell death in otherwise chemotherapy-resistant ovarian cancer stem cells. These results were later published in the August 2011 issue of Molecular Cancer Therapeutics. In additional pre-clinical studies, ME-344 has demonstrated far superior anti-tumor activity against a broad range of human cancer cell lines compared to NV-128.

About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company's lead drug candidates, ME-143 and ME-344, have been shown to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism, a function critical for cancer cell survival. Marshall Edwards initiated a Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors in September 2011 and expects to collect final safety and pharmacokinetic data from the trial by June 2012. The Company submitted an Investigational New Drug application for ME-344 in March 2012 and plans to initiate a Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors following approval by the FDA. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards CEO to Present at Roth Capital Partners Growth Stock Conference
2. Marshall Edwards Announces Rights Offering to Stockholders
3. Marshall Edwards Adds $2 Million in Private Placement
4. Marshall Edwards Announces $2 Million Private Placement
5. Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
6. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
7. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
8. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
9. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
10. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
11. Marshall Edwards Announces Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  BC Technical, the nation,s leading ... Medical Imaging, a leader in sales, service and installation ... allows BC Technical to continue to expand their resources ... and CT modalities. "We are committed ... Mark Alvarez , president and CEO of BC Technical. ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
(Date:8/29/2014)... WASHINGTON , Aug. 29, 2014 Diseases ... a generation ago are returning. Measles was declared ... cases in 2014 as of August 15—the highest incidence ... public health department declared whooping cough a problem ... children are getting sick and dying from these preventable ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... M.D., president of SPRI,Clinical Trials, will be a featured ... Group Investor Seminar -- Management,s Guide to,Wall Street. The ... Midtown,Loft & Terrace, 267 Fifth Avenue in New York. ... and small and mid-cap life science companies to gain,better ...
... In the news release, "Update on the SEAS Study" issued ... Principal Investigator & Head,of Steering Committee over PR Newswire, we ... information has been added to the,release:, , Satellite coordinates, ... Satellite: AB1 12.5 Deg West Txp: B6 Lower, ...
Cached Medicine Technology:/C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/ 2/C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/ 3
(Date:8/31/2014)... August 31, 2014 “Prohibition is ... (empiricism) is our future: the present ~ that’s ... Cannabinoid Science , new on the Bryan William ... on cannabinoid system (CS) modulation and homeostasis - ... chronic alcohol use. The Publius CS update includes: ...
(Date:8/31/2014)... 2014 Future Health, a market-leading ... firm that focuses on helping doctors utilize technology ... congruent commitment with the creators of education based ... create an environment that assists doctors to operate ... with patients,” says Steven Kraus, founder and CEO ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 Brook ... award winning, “Simplicity & Sophistication: Short Stories of ... and narrated by Dr. James W. Jackson author, speaker, ... Dr. Jackson compresses his vast volume of ... decades into over 150 countries on behalf of ...
(Date:8/31/2014)... The severity of menopausal symptoms will ... menopause is expert in helping patients find the ... uncomfortable symptoms with the latest treatment options, including hormone ... variety of alternative treatments and products that can relieve ... may fall outside of what can be called conventional ...
(Date:8/31/2014)... Barcelona, Spain Sunday 31 August 2014: Mortality ... at one year despite good use of oral anticoagulants, ... Atrial Fibrillation General Pilot Registry. The findings were presented ... by registry chairperson Professor Gregory Lip (Birmingham, UK). , ... sponsored registry focused on management practices of European cardiologists ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Publius’ Alcohol Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2
... of Dental Implants with Laser-Lok(R) Technology over Traditional ... in the dental implant industry, reported today that ... of implants with Laser-Lok (R) surface treatment ... vitro and in animal studies. Laser-Lok implants ...
... may drive the connection, researchers say , , TUESDAY, May ... lasting effects not just on her own health but ... , "Children with asthmatic parents are at an increased ... pregnancy," said H.A. Smit, head of the department of ...
... Escalon Medical Corp. (Nasdaq: ESMC ) ... March 31, 2009. For the third quarter of fiscal ... compared with $8,188,000 in the third quarter of fiscal ... third quarter of fiscal 2009, a 12.7% increase, compared ...
... How Executives and Employees are evaluated and paid is ... the Society of Corporate Compliance and Ethics and the ... that they want their employees to do the right ... bad behavior? The Society of Corporate Compliance and ...
... due to taking hormone replacement therapy appears to be the ... and without a family history, a University of Rochester Medical ... in the journal Epidemiology , adds to the evolving ... breast cancer risk among postmenopausal women. It also refutes the ...
... work of Julia Hippisley-Cox, Professor of Clinical Epidemiology and ... recognised by the Royal College of General Practitioners. , ... Fry Silver Medal an award made each year ... promoted the discipline of general practice through research and ...
Cached Medicine News:Health News:BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels 2Health News:BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels 3Health News:Overweight Moms More Likely to Have Asthmatic Kids 2Health News:Overweight Moms More Likely to Have Asthmatic Kids 3Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports Third Quarter Fiscal 2009 Results 8Health News:Executive Compensation Controversy Rages, SCCE to Determine What Role Compliance and Ethics Play 2Health News:HRT-breast cancer risk stays same, regardless of family history 2Health News:Prestigious award for 'outstanding' primary-care researcher 2Health News:Prestigious award for 'outstanding' primary-care researcher 3